Search
burosumab
Indications:
- X-linked hypophosphatemia
Dosage:
- 1 mg/kg every 2 weeks or 1.5 mg/kg every 4 weeks
Mechanism of action:
- monoclonal antibody that inhibits FGF-23
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
metabolic agent (metabolic modifier)
References
- Carpenter TO, Whyte MP, Imel EA
Burosumab Therapy in Children with X-Linked Hypophosphatemia.
N Engl J Med 2018; 378:1987-1998. May 24, 2018
PMID: 29791829
https://www.nejm.org/doi/full/10.1056/NEJMoa1714641